机器学习预测类风湿关节炎患者对TNF抑制剂的反应:基于ESPOIR和ABIRISK队列的结果
研究利用ESPOIR队列161例和ABIRISK队列118例类风湿关节炎患者数据,训练多种机器学习模型预测TNF抑制剂治疗反应。CatBoost模型在预测EULAR反应时表现最佳,训练集AUROC为0.72(0.68-0.73),验证集AUROC分别为0.70(0.57-0.82)和0.71(0.55-0.86)。DAS28变化预测平均误差为1.1分。
要点
- CatBoost模型预测EULAR反应训练集AUROC为0.72(0.68-0.73)。
- 验证集预测单抗和依那西普反应AUROC分别为0.70(0.57-0.82)和0.71(0.55-0.86)。
- 模型仅使用临床常规数据即可预测TNF抑制剂反应。
核心结论
- 所开发的机器学习模型可仅使用临床常规可获得的数据预测患者对TNF抑制剂的反应。
研究设计与样本
- 研究使用类风湿关节炎ESPOIR队列数据训练模型,终点为EULAR反应和DAS28变化。
- 比较线性回归、随机森林、XGBoost和CatBoost多种模型性能,并用交叉验证的AUROC或均方误差评估。
- 最佳模型在ABIRISK复制队列中进行评估。
- 训练集纳入ESPOIR队列161例患者,验证集纳入ABIRISK队列118例患者。
主要发现
- 筛选出的关键特征为DAS28、淋巴细胞、ALT(天冬氨酸氨基转移酶)、中性粒细胞、年龄、体重和吸烟状态。
- 预测EULAR反应时,CatBoost在四种测试模型中表现最佳,训练集(ESPOIR)AUROC为0.72(0.68-0.73)。
- 在训练集中分别分析依那西普和单克隆抗体时获得更好的结果。
- 在测试集(ABIRISK)中,上述模型分别达到AUROC 0.70(0.57-0.82)和0.71(0.55-0.86)。
- 测试了两种决策阈值:第一种优先高置信度识别反应者,预测反应的置信度高达90%;第二种优先高置信度识别反应不佳者,预测无反应的置信度高达70%。
关键数值与推荐
- CatBoost模型预测EULAR反应训练集AUROC为0.72(0.68-0.73)。
- 验证集预测依那西普和单抗反应AUROC分别为0.70(0.57-0.82)和0.71(0.55-0.86)。
- 高置信度识别反应者的阈值预测反应置信度高达90%。
- 高置信度识别反应不佳者的阈值预测无反应置信度高达70%。
- DAS28变化预测平均误差为1.1个DAS28分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Around 30% of patients with rheumatoid arthritis (RA) do not respond to tumour necrosis factor inhibitors (TNFi). We aimed to predict patient response to TNFi using machine learning on simple clinical and biological data. METHODS: We used data from the RA ESPOIR cohort to train our models. The endpoints were the EULAR response and the change in Disease Activity Score (DAS28). We compared the performances of multiple models (linear regression, random forest, XGBoost and CatBoost) on the training set and cross-validated them using the area under the receiver operating characteristic curve (AUROC) or the mean squared error. The best model was then evaluated on a replication cohort (ABIRISK). RESULTS: We included 161 patients from ESPOIR and 118 patients from ABIRISK. The key selected features were DAS28, lymphocytes, ALT (aspartate aminotransferase), neutrophils, age, weight, and smoking status. When predicting EULAR response, CatBoost achieved the best performances of the four tested models. It reached an AUROC of 0.72 (0.68-0.73) on the train set (ESPOIR). Better results were obtained on the train set when etanercept and monoclonal antibodies were analysed separately. On the test set (ABIRISK), these models respectively achieved on AUROC of 0.70 (0.57-0.82) and 0.71 (0.55-0.86). Two decision thresholds were tested. The first prioritised a high confidence in identifying responders and yielded a confidence up to 90% for predicting response. The second prioritised a high confidence in identifying inadequate responders and yielded a confidence up to 70% for predicting non-response. The change in DAS28 was predicted with an average error of 1.1 DAS28 points. CONCLUSION: The machine learning models developed allowed predicting patient response to TNFi exclusively using data available in clinical routine.
引用
- Bouget V, Duquesne J, Hassler S, et al. Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts. RMD Open. 2022. PMID: 35999028. doi:10.1136/rmdopen-2022-002442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。